Solid Biosciences (SLDB) Stock Forecast & Price Target

$9.29

+0.24 (+2.65%)

(As of 07/26/2024 ET)

Solid Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 9 Analyst Ratings

Based on 9 Wall Street analysts who have issued ratings for Solid Biosciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 8 have given a buy rating, and 1 has given a strong buy rating for SLDB.

Consensus Price Target

$16.17
74.02% Upside

High Forecast	$20.00
Average Forecast	$16.17
Low Forecast	$12.00

According to the 9 analysts' twelve-month price targets for Solid Biosciences, the average price target is $16.17. The highest price target for SLDB is $20.00, while the lowest price target for SLDB is $12.00. The average price target represents a forecasted upside of 74.02% from the current price of $9.29.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Buy	Buy	Buy	Hold
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	1 Buy rating(s)
Hold	0 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$16.17	$15.33	$18.25	$52.50
Forecasted Upside	74.02% Upside	78.26% Upside	43.76% Upside	460.54% Upside

Get Solid Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.

Ad The Oxford Club

Don't Pay a Dime for Marc Lichtenfeld's Top AI Picks

Usually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...

Click here now to claim your FREE copy of Marc's AI playbook.

SLDB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SLDB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Solid Biosciences Stock vs. The Competition

Type	Solid Biosciences	Medical Companies	S&P 500
Consensus Rating Score	3.11	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	74.02% Upside	3,123.51% Upside	9.18% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/15/2024	JPMorgan Chase & Co. 3 of 5 stars		Upgrade	Neutral ➝ Overweight	$10.00 ➝ $15.00	+89.63%
6/24/2024	Leerink Partnrs 0 of 5 stars	J. Schwartz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/24/2024	SVB Leerink 1 of 5 stars		Upgrade	Market Perform ➝ Outperform	$12.00 ➝ $12.00	+85.76%
6/21/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $20.00	+203.03%
5/20/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. He Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00	+78.77%
5/16/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$21.00 ➝ $18.00	+95.02%
3/28/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Lugo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/15/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$16.00	+30.29%
9/22/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Duncan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
8/12/2022	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$105.00 ➝ $90.00	+670.42%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:30 AM ET.

SLDB Forecast - Frequently Asked Questions

What is Solid Biosciences' forecast for 2024?: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Solid Biosciences is $16.17, with a high forecast of $20.00 and a low forecast of $12.00.
Should I buy or sell Solid Biosciences stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLDB shares.
Does Solid Biosciences's stock price have much upside?: According to analysts, Solid Biosciences's stock has a predicted upside of 88.61% based on their 12-month stock forecasts.
Has Solid Biosciences been upgraded by Wall Street analysts recently?: Over the previous 90 days, Solid Biosciences's stock had 3 upgrades by analysts.
What analysts cover Solid Biosciences?: Solid Biosciences has been rated by research analysts at Barclays, HC Wainwright, JPMorgan Chase & Co., Leerink Partnrs, Piper Sandler, and SVB Leerink in the past 90 days.
Do Wall Street analysts like Solid Biosciences more than its competitors?: Analysts like Solid Biosciences more than other "medical" companies. The consensus rating for Solid Biosciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SLDB compares to other companies.